Changes in the Use of Hydrochlorothiazide and Other Antihypertensive Drugs in Switzerland in Association With the Swissmedic Safety Alert Regarding Non‐melanoma Skin Cancer: An Interrupted Time‐Series Analysis Using Swiss Claims Data
Our results suggest that the DHPC by Swissmedic in 2018 accelerated a pre-existing decline in the use of hydrochlorothiazide in Switzerland.
Authors
- Julia Spoendlin (ORCID: https://orcid.org/0000-0003-1632-1928)
- Anton Pottegård (ORCID: https://orcid.org/0000-0001-9314-5679)
- Christoph Meier (ORCID: https://orcid.org/0000-0002-7120-6378)
- Daphne Reinau (ORCID: https://orcid.org/0000-0002-9123-6590)
- Carola A. Huber (ORCID: https://orcid.org/0000-0002-2469-0435)
- Tamino Zappalà (ORCID: https://orcid.org/0009-0009-6382-9645)
Institutions
- University of Southern Denmark (DK)
- University of Basel (CH)
- University Hospital of Basel (CH)
- Helsana Group (Switzerland) (CH)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1002/pds.70005
- Citations
- 4
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 4.52